HealthCap
HealthCap
  • About
    • Our Story
    • Strategy
    • Partners
    • Team
    • Special Advisors
  • Our Commitment
    • ESG Policy
  • Investments
    • Portfolio Companies
    • Approved Products
  • News
    • Portfolio Companies
    • HealthCap
  • Contact & Legal
    • Contact Us
    • Privacy Policy
    • Cookie Policy
  • LinkedIn
  • Twitter
  • Wikipedia
HealthCap

HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

Read more

Portfolio Companies News

  • March 5, 2021
    Press release from the extraordinar...

    2021-03-05 At the extraordinary general meeting (the “EGM”) of Vicore Pharma Holding AB (publ) (the “Company”) held on 5 March 2021, the below resolutions were mainly passed. Due to the extraordinary situation resulting from the COVID-19 pandemic the EGM was carried out through postal v... read more

  • March 3, 2021
    Strongbridge Biopharma plc Reports ...

    ~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to U.S. Food & Drug Administration ~ ~ KEVEYIS® (dichlorphenamide) Full-Year 2020 Revenue of $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $21... read more

  • March 2, 2021
    Pulmonx Reports Fourth Quarter and ...

    REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2020 ended Decembe... read more

  • March 2, 2021
    Strongbridge Biopharma plc Announce...

     RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~ ~ Nearly 40 Percent of Prescription-Treated Endogenous Cushing’s Syndrome Patients in the U.S. Are Not Well-Contro... read more

  • March 2, 2021
    Fusion Pharmaceuticals To Expand Pi...

    Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tumors HAMILTON, ON and BOSTON, March 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on... read more

HealthCap Info

  • February 12, 2021
    Q4 2020 General Market Overview

Facts

  • 118

    Since the start in 1996, HealthCap funds have invested in 118 portfolio companies.

    Read more
  • 46

    46 of the portfolio companies have been taken public on nine different markets.

    Read more
  • 27

    27 of the portfolio companies pharmaceutical products have been approved for marketing.

    Read more
  • 12

    Unicorn Factory
    Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.

    Read more

Twitter

Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update @HealthCapVC
4 days ago
Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results @HealthCapVC
4 days ago

Subscribe to news

Venture Capital for Breakthrough Therapies

This site uses cookies. But first we need your consent. More info.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close